The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

Summary

The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance.

Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group.

Other tasks include:

* filling in quality of life (QOL) questionnaires at every time point;
* participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional);
* collecting blood at the follow-up time points for our secondary endpoint (optional).

Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.

Conditions

• Stage III Non-small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

18F FDG PET/CT

Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

DIAGNOSTIC_TEST

CT scan

CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

Sponsors & Collaborators

• Amsterdam UMC, location VUmc

  collaborator OTHER

• Streekziekenhuis Koningin Beatrix

  collaborator UNKNOWN

• Canisius-Wilhelmina Hospital

  collaborator OTHER

• Diakonessenhuis, Utrecht

  collaborator OTHER

• Dijklander Ziekenhuis

  collaborator OTHER

• Deventer Ziekenhuis

  collaborator OTHER

• Elisabeth-TweeSteden Ziekenhuis

  collaborator OTHER

• Gelre Hospitals

  collaborator OTHER

• Groene Hart Ziekenhuis

  collaborator OTHER

• HagaZiekenhuis

  collaborator OTHER

• Martini Hospital Groningen

  collaborator OTHER

• Medisch Spectrum Twente

  collaborator OTHER

• St. Antonius Hospital

  collaborator OTHER

• Franciscus &Vlietland

  collaborator OTHER

• Tjongerschans

  collaborator UNKNOWN

• Maasstadziekenhuis

  collaborator UNKNOWN

• Gelderse Vallei Hospital

  collaborator OTHER

• Bravis Hospital

  collaborator OTHER

• Tergooi Hospital

  collaborator OTHER

• Treant Zorggroep

  collaborator UNKNOWN

• Amphia Hospital

  collaborator OTHER

• UMC Utrecht

  collaborator OTHER

• OLVG

  collaborator NETWORK

• Haaglanden Medical Centre

  collaborator OTHER

• Antoni van Leeuwenhoek Hospital

  collaborator OTHER

• Radboud University Medical Center

  lead OTHER

Principal Investigators

• Iris Walraven, PhD. · Radboud University Medical Center

• Annemarie Becker-Commissaris, PhD./MD. · Amsterdam UMC

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-19

Primary Completion

2029-04-30

Completion

2029-06-30

Countries

• Netherlands

Study Locations